Blood-based liquid biopsy in advanced prostate cancer
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved..
Prostate cancer is characterized by several genetic alterations which could impact prognosis and therapeutic decisions in the advanced disease. Tissue biopsy is still considered the gold standard approach for molecular characterization in prostate cancer, but it has several limitations, including the possibility of insufficient/inadequate tumor tissue to be analyzed. Blood-based liquid biopsy is a non-invasive method to investigate tumor cell derivatives in the bloodstream, being a valid alternative to tissue biopsy for molecular characterization but also for predictive and/or prognostic purposes. In this review, we analyze the most relevant evidence in this field, focusing on clinically relevant targets such as HRD genetic alterations and also focusing on the differences between tissue and liquid biopsy in light of the data from the latest clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:194 |
|---|---|
| Enthalten in: |
Critical reviews in oncology/hematology - 194(2024) vom: 19. Feb., Seite 104241 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giunta, Emilio Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 06.02.2024 Date Revised 06.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.critrevonc.2023.104241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366135791 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366135791 | ||
| 003 | DE-627 | ||
| 005 | 20240206232049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2023.104241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM366135791 | ||
| 035 | |a (NLM)38122919 | ||
| 035 | |a (PII)S1040-8428(23)00329-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giunta, Emilio Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blood-based liquid biopsy in advanced prostate cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2024 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Prostate cancer is characterized by several genetic alterations which could impact prognosis and therapeutic decisions in the advanced disease. Tissue biopsy is still considered the gold standard approach for molecular characterization in prostate cancer, but it has several limitations, including the possibility of insufficient/inadequate tumor tissue to be analyzed. Blood-based liquid biopsy is a non-invasive method to investigate tumor cell derivatives in the bloodstream, being a valid alternative to tissue biopsy for molecular characterization but also for predictive and/or prognostic purposes. In this review, we analyze the most relevant evidence in this field, focusing on clinically relevant targets such as HRD genetic alterations and also focusing on the differences between tissue and liquid biopsy in light of the data from the latest clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Liquid biopsy | |
| 650 | 4 | |a Molecular oncology | |
| 650 | 4 | |a Precision oncology | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Malapelle, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a De Giorgi, Ugo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology/hematology |d 1996 |g 194(2024) vom: 19. Feb., Seite 104241 |w (DE-627)NLM012606006 |x 1879-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:194 |g year:2024 |g day:19 |g month:02 |g pages:104241 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.critrevonc.2023.104241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 194 |j 2024 |b 19 |c 02 |h 104241 | ||